

Bioengineered
Volume 4, Issue 3
Adit Naor and Uri Gophna
Bioengineered
Volume 4, Issue 3
Christina Schümann, Herbert Michlmayr, Andrés M. del Hierro, Klaus D. Kulbe, Vladimir Jiranek, Reinhard Eder and Thu-Ha Nguyen
Bioengineered
Volume 4, Issue 3
Juan Nogales, Steinn Gudmundsson and Ines Thiele
Bioengineered
Volume 4, Issue 3
Aisling O’ Driscoll and Roy D. Sleator
Bioengineered
Volume 4, Issue 3
Charles Gauci and Marshall W. Lightowlers
About the cover
Colorized electron micrograph of probiotic Escherichia coli G3/10 and probiotic yeast Saccharomyces boulardii.
The image was prepared by Carolin Büttner, Institute of Medical Microbiology and Hygiene, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany together with Manfred Rohde, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Open access fees will be waived for all original research papers published in 2013!
Medline/PubMed, PubMed Central, CABI (Global Health, CAB Abstracts)
A targeted genetic approach was also followed. Two homologs of the Saccharomyces cerevisiae GAS1, AgGAS1A (AGL351W) and AgGAS1B (AGL352W), were deleted from the A. gossypii genome. For both copies deletion, a new antibiotic marker cassette conferring resistance to phleomycin, BLE3, was constructed. GAS1 encodes an β-1,3-glucanosyltransglycosylase involved in cell wall assembly. Higher permeability of the cell wall was expected to increase the protein secretion capacity. However, total protein secreted to culture supernatants and secreted EGI activity did not increase in the Aggas1AΔ mutants. Deletion of the AgGAS1B copy affected cellular morphology and resulted in severe retardation of growth, similarly to what has been reported for GAS1-defficient yeast. Thus, secretion could not be tested in these mutants.
Flavonols extracts presented high antioxidant activity as compared with anthocyanins and standards antioxidants (ascorbic acid and quercetin). Allium cepa and Crataegus oxyacantha ssp monogyna exhibited the most effective antimicrobial activity.
In summary, the pre-clinical evaluation has demonstrated the efficacy of LIVP6.1.1 for canine cancer therapy. Furthermore, a clinical trial with canine cancer patients has already been started.

